<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the antihyperglycemic effects of phloridzin, it has some limitations, including poor absorption, rapid degradation and low bioavailability [
 <xref rid="B7-ijms-22-00962" ref-type="bibr">7</xref>]. Phloridzin itself is not developed as a drug but, currently, some phloridzin-derived SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, ertugliflozin, tofogliflozin and luseogliflozin) have gained approval in some developed countries [
 <xref rid="B10-ijms-22-00962" ref-type="bibr">10</xref>].
</p>
